title: Phase I-II study of epirubicin in multiple myeloma.
abstract: Forty patients with relapsed (26) or refractory (14) myeloma were treated with epirubicin of doses of 75, 90, 105, and 120 mg/m2 in groups of 6 or more patients to test for response, maximum tolerated dose, and toxicity. Thirteen patients had received prior doxorubicin and were included in the dose findings part of the study only. Staging was I (1), II (5), and III (34). Partial responses were seen in 5 patients (18.5%) (duration 1.5, 2, 2.5, 10, and 18 months) not previously treated with doxorubicin. No responses were seen in patients treated with prior anthracycline. Responses were not dependent upon dose level of epirubicin. Median nadir white blood cell count at the four-dose levels were 2,300, 1,000, 1,600, and 1,700/mm3 with median nadir granulocyte counts of 897, 720, 688, and 192/mm3. Fever/neutropenia was infrequently observed at the three lower dose levels but occurred in 6 of 10 patients at 120 mg/m2. Platelet nadirs were 110,000, 83,000, 169,000, and 42,000/mm3. Nonhematological toxicity was not dose dependent and included alopecia (100%), nausea/vomiting (40%), and stomatitis (25%). Six patients had greater than or equal to 0.10 changes in the resting ejection fraction with one patient developing congestive heart failure that responded to medical management. This patient had received prior doxorubicin and had a history of myocardial infarction. Epirubicin can produce remissions in patients with previously treated myeloma who have not received prior doxorubicin. Since the response rate was not enhanced at 120/m2 and since fever/neutropenia was seen regularly at this dose level, the recommended dose for further study is 105 mg/m2.
authors.affiliation: Department of Medicine, Maine Medical Center, Portland 04102.
authors.forename: D C
authors.initials: DC
authors.lastname: Case
authors.forename: T J
authors.initials: TJ
authors.lastname: Ervin
authors.forename: R
authors.initials: R
authors.lastname: Gams
authors.forename: H L
authors.initials: HL
authors.lastname: Sonneborn
authors.forename: S D
authors.initials: SD
authors.lastname: Paul
authors.forename: F B
authors.initials: FB
authors.lastname: Oldham
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D015251:Epirubicin / Q000009:adverse effects / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*
chemical_list: D015251:Epirubicin